(Q36655034)

15 August 2017

1 reference

title

Antimicrobial-associated QT interval prolongation: pointes of interest (English)

1 reference

15 August 2017

2

Thomas D Nolin

1 reference

15 August 2017

Robert C Owens

1

1 reference

15 August 2017

language of work or name

English

0 references

publication date

8 November 2006

1 reference

Clinical Infectious Diseases

15 August 2017

published in

1 reference

15 August 2017

volume

43

1 reference

15 August 2017

issue

12

1 reference

15 August 2017

page(s)

1603-1611

1 reference

QTc interval in the assessment of cardiac risk

15 August 2017

cites work

1 reference

Drugs, QTc interval prolongation and final ICH E14 guideline : an important milestone with challenges ahead

21 January 2018

1 reference

QT prolongation with antimicrobial agents: understanding the significance

21 January 2018

1 reference

Measurement and interpretation of QT dispersion.

21 January 2018

1 reference

Diurnal pattern of QTc interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events.

21 January 2018

1 reference

Effect of coronary ischemia on QT dispersion

21 January 2018

1 reference

Effects of antiarrhythmic drugs on QT interval dispersion--relationship to antiarrhythmic action and proarrhythmia

21 January 2018

1 reference

Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management

21 January 2018

1 reference

Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview

21 January 2018

1 reference

Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling

21 January 2018

1 reference

Measurement of the QT interval and the risk associated with QTc interval prolongation: a review

21 January 2018

1 reference

Drug-induced prolongation of the QT interval

21 January 2018

1 reference

QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience

21 January 2018

1 reference

The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology

21 January 2018

1 reference

Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS.

21 January 2018

1 reference

Antimicrobial safety: focus on fluoroquinolones

21 January 2018

1 reference

Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors

21 January 2018

1 reference

Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus

21 January 2018

1 reference

Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing

21 January 2018

1 reference

Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition

21 January 2018

1 reference

Clinical significance of the cytochrome P450 2C19 genetic polymorphism

21 January 2018

1 reference

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

21 January 2018

1 reference

Optimizing antimicrobial dosing in the critically ill patient

21 January 2018

1 reference

Hepatic drug metabolism and transport in patients with kidney disease.

21 January 2018

1 reference

Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System

21 January 2018

1 reference

Characterization of the inhibitory effects of erythromycin and clarithromycin on the HERG potassium channel

21 January 2018

1 reference

Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics

21 January 2018

1 reference

QT prolongation and torsades de pointes associated with concurrent use of cisapride and erythromycin

21 January 2018

1 reference

Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism

21 January 2018

1 reference

Torsade de pointes. Mechanisms and management.

21 January 2018

1 reference

Use of terfenadine and contraindicated drugs

21 January 2018

1 reference

Oral erythromycin and the risk of sudden death from cardiac causes

21 January 2018

1 reference

The influence of cisapride and clarithromycin on QT intervals in healthy volunteers.

21 January 2018

1 reference

Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6).

21 January 2018

1 reference

QT prolongation and Torsades de Pointes associated with clarithromycin

21 January 2018

1 reference

Torsade de pointes induced by cisapride/clarithromycin interaction

21 January 2018

1 reference

Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin

21 January 2018

1 reference

Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects

21 January 2018

1 reference

Torsade de pointes and cardiorespiratory arrest induced by azithromycin in a patient with congenital long QT syndrome

21 January 2018

1 reference

QT prolongation associated with azithromycin/amiodarone combination

21 January 2018

1 reference

Azithromycin and terfenadine: lack of drug interaction.

21 January 2018

1 reference

Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin

21 January 2018

1 reference

Safety profile of the quinolones

21 January 2018

1 reference

Clinical use of the fluoroquinolones

21 January 2018

1 reference

QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome

21 January 2018

1 reference

Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors

21 January 2018

1 reference

Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors

21 January 2018

1 reference

A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia

21 January 2018

1 reference

Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome

21 January 2018

1 reference

Chlamydia pneumoniae and acute coronary syndrome

21 January 2018

1 reference

Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three italian regions.

21 January 2018

1 reference

The effects of levofloxacin on ECG parameters and late potentials

21 January 2018

1 reference

Effects of three fluoroquinolones on QT analysis after standard treatment courses.

21 January 2018

1 reference

Systemic antifungal agents. Drug interactions of clinical significance

21 January 2018

1 reference

Voriconazole-induced QT interval prolongation and ventricular tachycardia: a non-concentration-dependent adverse effect.

21 January 2018

1 reference

Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline

21 January 2018

1 reference

Fluconazole-induced torsade de pointes

21 January 2018

1 reference

Diuretics in nonedematous states. Physiological basis for the clinical use.

21 January 2018

1 reference

Voriconazole therapeutic drug monitoring.

21 January 2018

1 reference

Pentamidine reduces hERG expression to prolong the QT interval

21 January 2018

1 reference

Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells.

21 January 2018

1 reference

Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1086/508873

1 reference

15 August 2017

1 reference